Prehypertensive treatment with losartan, however not amlodipine, leads to long‑term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke‑prone rats

Zhang,Liangmin; He,Dehua; Lin,Jinxiu

doi:10.3892/mmr.2015.4641

Prehypertensive treatment with losartan, however not amlodipine, leads to long‑term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke‑prone rats

Authors:
- Liangmin Zhang
- Dehua He
- Jinxiu Lin
View Affiliations

Affiliations: Department of Cardiology, The First Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China
Published online on: December 4, 2015 https://doi.org/10.3892/mmr.2015.4641
Pages: 1304-1310

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke‑prone (SHRSP) rats against the risk of stroke. SHRSP rats were administered losartan, amlodipine or the vehicle for 6 weeks. There were no significant differences in systolic blood pressure (SBP) in rats treated with losartan or amlodipine, however, following drug withdrawal, rats treated with losartan maintained reduced SBP for a longer time compared with rats treated with amlodipine. In addition, rats treated with losartan exhibited thinner vascular walls and improved systolic and diastolic function. Clinical stroke scores in the losartan group were significantly reduced compared with those in the amlodipine and vehicle groups. However, rats treated with losartan exhibited higher levels of angiotensin II and lower levels of aldosterone in the serum and brain cortex compared with the vehicle and amlodipine‑treated rats. Furthermore, losartan significantly reduced the abnormal expression of angiotensin II receptors type 1 and 2 in SHRSP rats, whilst amlodipine did not. These results suggest that losartan may be more efficacious than amlodipine in ameliorating blood pressure deterioration and reducing stroke risk in SHRSP rats via regulation of the renin angiotensin system.

View Figures

View References

1	Lee M, Saver JL, Chang B, Chang KH, Hao Q and Ovbiagele B: Presence of baseline prehypertension and risk of incident stroke: A meta-analysis. Neurology. 77:1330–1337. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sipahi I, Swaminathan A, Natesan V, Debanne SM, Simon DI and Fang JC: Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: A meta-analysis of randomized controlled trials. Stroke. 43:432–440. 2012. View Article : Google Scholar
3	Takemori K, Ishida H and Ito H: Continuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive rats. Life Sci. 77:2233–2245. 2005. View Article : Google Scholar : PubMed/NCBI
4	Hamaguchi R, Takemori K, Inoue T, Masuno K and Itox H: Short-term treatment of stroke-prone spontaneously hypertensive rats with an AT1 receptor blocker protects against hypertensive end-organ damage by prolonged inhibition of the renin-angiotensin system. Clin Exp Pharmacol Physiol. 35:1151–1155. 2008. View Article : Google Scholar : PubMed/NCBI
5	Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 359:995–1003. 2002. View Article : Google Scholar : PubMed/NCBI
6	McLachlan J, Beattie E, Murphy MP, Koh-Tan CH, Olson E, Beattie W, Dominiczak AF, Nicklin SA and Graham D: Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ₁₀, and angiotensin receptor blocker, losartan, on cardiovascular function. J Hypertens. 32:555–564. 2014. View Article : Google Scholar :
7	Judd E and Jaimes EA: Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. Expert Rev Cardiovasc Ther. 10:293–303. 2012. View Article : Google Scholar : PubMed/NCBI
8	Messerli FH and Staessen JA: Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. Hypertension. 48:359–361. 2006. View Article : Google Scholar : PubMed/NCBI
9	Wang JG, Li Y, Franklin SS and Safar M: Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: A quantitative overview. Hypertension. 50:181–188. 2007. View Article : Google Scholar : PubMed/NCBI
10	He DH, Zhang LM, Lin LM, Ning RB, Wang HJ, Xu CS and Lin JX: Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. Int J Mol Med. 33:301–309. 2014.
11	Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, et al VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 363:2022–2031. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T and Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group: Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 51:393–398. 2008. View Article : Google Scholar : PubMed/NCBI
13	Yamori Y, Horie R, Akiguchi I, Kihara M, Nara Y and Lovenberg W: Symptomatological classification in the development of stroke in stroke-prone spontaneously hypertensive rats. Jpn Circ J. 46:274–283. 1982. View Article : Google Scholar : PubMed/NCBI
14	Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD and Eguchi S: Angiotensin II signal transduction through the AT1 receptor: Novel insights into mechanisms and pathophysiology. Clin Sci (Lond). 112:417–428. 2007. View Article : Google Scholar
15	Lin JX and Lin LM: Prehypertensive treatment in spontaneously hypertensive rats: A comparison of losartan and amlodipine regarding blood pressure control and cardiovascular protection after drug withdrawal. Int J Cardiol. 137:S1322009. View Article : Google Scholar
16	Morton JJ, Beattie EC and MacPherson F: Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: Lack of relation to vascular structure. J Vasc Res. 29:264–269. 1992. View Article : Google Scholar : PubMed/NCBI
17	Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F and Lever AF: Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension. 16:603–614. 1990. View Article : Google Scholar : PubMed/NCBI
18	Ishiguro K, Sasamura H, Sakamaki Y, Itoh H and Saruta T: Developmental activity of the renin-angiotensin system during the “critical period” modulates later L-NAME-induced hypertension and renal injury. Hypertens Res. 30:63–75. 2007. View Article : Google Scholar : PubMed/NCBI
19	Sasamura H, Hayashi K, Ishiguro K, Nakaya H, Saruta T and Itoh H: Prevention and regression of hypertension: Role of renal microvascular protection. Hypertens Res. 32:658–664. 2009. View Article : Google Scholar : PubMed/NCBI
20	Bergström G, Johansson I, Wickman A, Gan L and Thorup C: Brief losartan treatment in young spontaneously hypertensive rats abates long-term blood pressure elevation by effects on renal vascular structure. J Hypertens. 20:1413–1421. 2002. View Article : Google Scholar : PubMed/NCBI
21	Edvinsson L: Cerebrovascular angiotensin AT1 receptor regulation in cerebral ischemia. Trends Cardiovasc Med. 18:98–103. 2008. View Article : Google Scholar : PubMed/NCBI
22	Kasahara Y, Taguchi A, Uno H, Nakano A, Nakagomi T, Hirose H, Stern DM and Matsuyama T: Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res. 1340:70–80. 2010. View Article : Google Scholar : PubMed/NCBI
23	Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T and Horiuchi M: Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 110:843–848. 2004. View Article : Google Scholar : PubMed/NCBI
24	McCarthy CA, Vinh A, Callaway JK and Widdop RE: Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke. 40:1482–1489. 2009. View Article : Google Scholar : PubMed/NCBI
25	Denker MG and Cohen DL: What is an appropriate blood pressure goal for the elderly: Review of recent studies and practical recommendations. Clin Interv Aging. 8:1505–1517. 2013.PubMed/NCBI
26	Umemoto S, Ogihara T, Rakugi H, Matsumoto M, Kitagawa K, Shimada K, Higaki J, Ito S, Suzuki H, Ohashi Y, et al Combination Therapy of Hypertension to Prevent Cardiovascular: Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: The COPE trial. Hypertens Res. 36:1088–1095. 2013. View Article : Google Scholar : PubMed/NCBI
27	Aronow WS: Hypertension-related stroke prevention in the elderly. Curr Hypertens Rep. 15:582–589. 2013. View Article : Google Scholar : PubMed/NCBI